Key result
Olmesartan was associated with an adverse drug reaction frequency of 0.4% and a ~90% blood pressure response rate in a pooled analysis of 156,682 hypertensive patients.
Why the study?
Does olmesartan safely reduce blood pressure and achieve targets in hypertensive patients?
Observational (n=156,682)
Yes
Does olmesartan safely reduce blood pressure and achieve targets in hypertensive patients?
Olmesartan is well tolerated and achieves high responder rates, though strict blood pressure targets are achieved in a minority of high-risk patients in real-world settings.
Supports olmesartan tolerability in large real-world cohorts; leaves open need for randomized confirmation before practice change.
BACKGROUND: Angiotensin type 1 receptor blockers are recommended for first-line antihypertensive treatment. METHODS: We performed a pooled-analysis of 20 post-authorization surveys of olmesartan involving 156,682 hypertensive patients. Olmesartan was used as monotherapy or in combination with other antihypertensive drugs, for example, hydrochlorothiazide. OBJECTIVES: We assessed the safety of olmesartan by monitoring adverse drug reactions (ADRs). The number of patients achieving systolic and diastolic blood pressure (BP) targets (< 140/90 mmHg in the overall population, < 130/80 mmHg in high-risk patients) or responding to treatment (BP decrease of ≥ 20/10 mmHg) was also determined. RESULTS: In all, 43.8% of patients received olmesartan monotherapy, 29% olmesartan with hydrochlorothiazide and 27.2% olmesartan in combination with other antihypertensives. The frequency of ADRs was 0.4% and not altered by dose, age ≥ 65 years or presence of co-morbidities. About 90% of patients were responders. Blood pressure targets were achieved in 52.8 and 35.7% of patients without risk factors and in the overall cohort, but only in 8.1 and 27.5% of patients with renal dysfunction or taking NSAIDs. CONCLUSION: Olmesartan was very well tolerated. Responder rates to olmesartan were high, although BP targets were only achieved in a minority of patients at high risk, with renal dysfunction or taking NSAIDs.
No takes yet. Share an insight, caveat, or question.
Scholze et al. (2011) conducted an observational in Hypertension (n=156,682). Olmesartan was evaluated on Adverse drug reactions (ADRs). Olmesartan was associated with an adverse drug reaction frequency of 0.4% and a ~90% blood pressure response rate in a pooled analysis of 156,682 hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: